Inflammation and immunogenicity limit the utility of the rabbit as a nonclinical species for ocular biologic therapeutics
Abstract
The nonclinical safety evaluation of therapeutic drug candidates is commonly conducted in two species (rodent and non-rodent) in keeping with international health authority guidance. Biologic drugs typically have restricted species cross-reactivity, necessitating the evaluation of safety in non-human primates and thus limiting the utility of lower order species. Safety studies of cross-reactive ocular biologic drug candidates have been conducted...
Paper Details
Title
Inflammation and immunogenicity limit the utility of the rabbit as a nonclinical species for ocular biologic therapeutics
Published Date
Jun 1, 2017
Volume
86
Pages
221 - 230
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History